- Concomitant medications during immune checkpoint blockage in cancer patients: Novel insights in this emerging clinical scenario
Giovanni Rossi et al, 2019, Critical Reviews in Oncology/Hematology CrossRef - Intestinal Microbiota: A Novel Target to Improve Anti-Tumor Treatment?
Romain Villéger et al, 2019, IJMS CrossRef - Antibiotic use and the efficacy of immune checkpoint inhibitors in cancer patients: a pooled analysis of 2740 cancer patients
Xuan-Zhang Huang et al, 2019, OncoImmunology CrossRef - Antibiotic therapy and outcome from immune-checkpoint inhibitors
David J. Pinato et al, 2019, j. immunotherapy cancer CrossRef - Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer
Carmine Carbone et al, 2019, Mediators of Inflammation CrossRef - The Cross-Talk Between Gut Microbiota and Lungs in Common Lung Diseases
Dapeng Zhang et al, 2020, Front. Microbiol. CrossRef - Survival of Patients Treated with Antibiotics and Immunotherapy for Cancer: A Systematic Review and Meta-Analysis
Fausto Petrelli et al, 2020, JCM CrossRef - The Gut Microbiota and Respiratory Diseases: New Evidence
Li Chunxi et al, 2020, Journal of Immunology Research CrossRef - A Significant Question in Cancer Risk and Therapy: Are Antibiotics Positive or Negative Effectors? Current Answers and Possible Alternatives
Steffanie S. Amadei et al, 2020, Antibiotics CrossRef - Multivariable Analysis of 169 Cases of Advanced Cutaneous Melanoma to Evaluate Antibiotic Exposure as Predictor of Survival to Anti-PD-1 Based Immunotherapies
Umang Swami et al, 2020, Antibiotics CrossRef - Is the survival of patients treated with ipilimumab affected by antibiotics? An analysis of 1585 patients from the French National hospital discharge summary database (PMSI)
Pierre-Yves Cren et al, 2020, OncoImmunology CrossRef - Pleiotropic Effects of Metformin on the Antitumor Efficiency of Immune Checkpoint Inhibitors
Wenhui Liu et al, 2021, Front. Immunol. CrossRef - Relating Gut Microbiome and Its Modulating Factors to Immunotherapy in Solid Tumors: A Systematic Review
Chengliang Huang et al, 2021, Front. Oncol. CrossRef - Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs)
Nicholas Giustini et al, 2021, LCTT CrossRef - Gut Microbiota and Gynecological Cancers: A Summary of Pathogenetic Mechanisms and Future Directions
Fulvio Borella et al, 2021, ACS Infect. Dis. CrossRef - Effect of antibiotic use on the efficacy of nivolumab in the treatment of advanced/metastatic non-small cell lung cancer: A meta-analysis
Geng-wei Huo et al, 2021 CrossRef - Diet, Microbiome, and Cancer Immunotherapy—A Comprehensive Review
Michał Szczyrek et al, 2021, Nutrients CrossRef - Impact of Proton Pump Inhibitor Use on the Effectiveness of Immune Checkpoint Inhibitors in Advanced Cancer Patients
Kangning Peng et al, 2021, Ann Pharmacother CrossRef - Effects of concomitant proton pump inhibitor use on immune checkpoint inhibitor efficacy among patients with advanced cancer
Bao-Dong Qin et al, 2021, OncoImmunology CrossRef - The Emerging Role of the Gut Microbiome in the Cancer Response to Immune Checkpoint Inhibitors: A Narrative Review
Ghada Araji et al, 2022 CrossRef - Effects of Concomitant Antibiotics Use on Immune Checkpoint Inhibitor Efficacy in Cancer Patients
Shuai Jiang et al, 2022, Front. Oncol. CrossRef - An Up-To-Date Investigation Into the Correlation Between Proton Pump Inhibitor Use and the Clinical Efficacy of Immune Checkpoint Inhibitors in Advanced Solid Cancers: A Systematic Review and Meta-Analysis
Chaoxing Liu et al, 2022, Front. Oncol. CrossRef - How Could Antibiotics, Probiotics, and Corticoids Modify Microbiota and Its Influence in Cancer Immune Checkpoint Inhibitors: A Review.
Mara Cruellas et al, 2021, Infect Immun CrossRef - The association between proton pump inhibitor use and systemic anti‐tumour therapy on survival outcomes in patients with advanced non‐small cell lung cancer: A systematic review and meta‐analysis
Na Wei et al, 2022, Brit J Clinical Pharma CrossRef - Real-World Effectiveness of Immunotherapies in Pre-Treated, Advanced Non-Small Cell Lung Cancer Patients: A Systematic Literature Review
Ariadna Juarez-Garcia et al, 2022, Lung Cancer CrossRef - Impact of Proton Pump Inhibitors and Histamine-2-Receptor Antagonists on Non-Small Cell Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis
Alessandro Rizzo et al, 2022, Cancers CrossRef - Prognostic value of immunotherapy-induced organ inflammation assessed on 18FDG PET in patients with metastatic non-small cell lung cancer
Olivier Humbert et al, 2022, Eur J Nucl Med Mol Imaging CrossRef - Gut Microbiota and Immunotherapy
Xiaoqing Xu et al, 2022, Front. Microbiol. CrossRef - The Correlation between the Use of the Proton Pump Inhibitor and the Clinical Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Da-Hai Hu et al, 2022, Journal of Oncology CrossRef - The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer
Philip Bredin et al, 2022, Cancer Metastasis Rev CrossRef - Global research trends on the links between gut microbiota and cancer immunotherapy: A bibliometric analysis (2012-2021).
Shanshan Yang et al, 2022, Front Immunol CrossRef - The Crosstalk between Microbiome and Immunotherapeutics: Myth or Reality
Alireza Tojjari et al, 2022, Cancers CrossRef - Non-Invasive Biomarkers for Immunotherapy in Patients with Hepatocellular Carcinoma: Current Knowledge and Future Perspectives
Maria Pallozzi et al, 2022, Cancers CrossRef - Microbiota and Extracellular Vesicles in Anti-PD-1/PD-L1 Therapy
Surbhi Mishra et al, 2022, Cancers CrossRef - Combination Use of First-Line Afatinib and Proton-Pump Inhibitors Reduces Overall Survival Among Patients with EGFFR Mutant Lung Cancer
Meng-Chin Ho et al, 2022, OTT CrossRef - Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis
Sébastien Lopes et al, 2023, Front. Immunol. CrossRef - A systematic review and meta-analysis evaluating the impact of antibiotic use on the clinical outcomes of cancer patients treated with immune checkpoint inhibitors
Athéna Crespin et al, 2023, Front. Oncol. CrossRef - Non-small cell lung cancer patients treated with Anti-PD1 immunotherapy show distinct microbial signatures and metabolic pathways according to progression-free survival and PD-L1 status
David Dora et al, 2023, OncoImmunology CrossRef - Influence of Antibiotic Use on the Effectiveness and Safety of Immune Checkpoint Inhibitors
Takuya Minamishima et al, 2022, Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) CrossRef - Analysis of the relation between adverse events and overall survival in patients treated with pembrolizumab as a first-line treatment for metastatic NSCLC
Lisa Faoro et al, 2023, BMC Pharmacol Toxicol CrossRef - Oncological relevance of gut and urine microbiomes
Csilla Oláh et al, 2021, Orv Hetil CrossRef - Causal effects of gut microbiota in the development of lung cancer and its histological subtypes: A Mendelian randomization study
Yunlei Ma et al, 2024, Thoracic Cancer CrossRef - Gut microbiota and dietary intervention: affecting immunotherapy efficacy in non–small cell lung cancer
Yu Xin et al, 2024, Front. Immunol. CrossRef - Biomarkers and computational models for predicting efficacy to tumor ICI immunotherapy
Yurong Qin et al, 2024, Front. Immunol. CrossRef - Effectiveness and Safety of PD-1 Inhibitors’ Treatment for Patients with Non-Small-Cell Lung Cancer in China: A Real-World Study
Ning Wan et al, 2024, European Journal of Cancer Care CrossRef - Effects of antibiotics on the anti-tumor efficacy of immune checkpoint inhibitor therapy
Fangfang Nie et al, 2024, Clin Transl Oncol CrossRef - Antibiotic adoption effects on nutrition and quality of life in lung cancer patients undergoing radiotherapy and chemotherapy: A meta-analysis
Zhifeng Zhao et al, 2024, THC CrossRef